Skip to main content
Back
ANRO logo

Alto Neuroscience, Inc.

Data quality: 100%
ANRO
NYSE Healthcare Biotechnology
$20.19
▲ $0.17 (0.85%)
Mkt Cap: 627.23M
Day Range
$19.41 $20.46
52-Week Range
$1.60 $25.17
Volume
140,803
50D / 200D Avg
$18.43 / $10.24
Prev Close
$20.02

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -9.9 0.3
P/B 4.2 2.9
ROE % -41.8 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

Analyst Price Target

Hold
$26.33 +30.4%
Low: $16.00 High: $35.00
Forward EPS
-$2.41
Est. Revenue
0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.09
$1.09 – $1.09
290 M 2
FY2029 -$2.41
-$2.41 – -$2.41
49 M 4
FY2028 -$2.88
-$4.11 – -$2.15
9.3 M 6

Key Takeaways

Debt/Equity of 0.03 — conservative balance sheet
Negative free cash flow of -51.79M
PEG of 0.65 suggests growth is underpriced

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-41.80%
ROIC-32.00%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.03
Current Ratio15.69
Interest Coverage-26.88

Valuation

P/E Ratio
-9.92
P/B Ratio4.15
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -63.24M
ROE -41.80% ROA -34.24%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -51.79M
ROIC -32.00% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.03 Current Ratio 15.69
Interest Coverage -26.88 Dividend Yield 0.00%
Valuation
P/E Ratio -9.92 P/B Ratio 4.15
P/S Ratio N/A PEG Ratio 0.65
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 627.23M Enterprise Value 455.15M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 210,000.0
Net Income -63.24M -61.43M -36.31M -27.71M -9.19M
EPS (Diluted) -2.19 -2.50 -1.35 -1.08 -0.36
Gross Profit -661,000.0 -502,000.0 0.0 -342,000.0 65,000.0
Operating Income -66.36M -68.61M -37.81M -29.19M -12.06M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 184.69M 177.54M 86.63M 50.85M 28.79M
Total Liabilities 33.55M 26.08M 158.30M 89.26M 41.27M
Shareholders' Equity 151.14M 151.46M -71.67M -38.41M -12.48M
Total Debt 4.41M 16.94M 9.99M 82.11M 38.16M
Cash & Equivalents 176.48M 168.23M 82.55M 48.34M 25.71M
Current Assets 177.72M 169.34M 85.39M 49.22M 27.68M
Current Liabilities 11.33M 10.01M 5.61M 5.56M 1.81M